Drug
Satraplatin clinical trials
- studies test it
- 14
- open now
- 0
- in phase 3
- 2
- first study started
- 2003
How studies write it
Studies that test it under each name
Name
Development codes
Combined with it in one product
Studies by the year they started
14 studies that test it; most in 2007 (5)
| Year | Studies |
|---|---|
| 2003 | 1 |
| 2004 | 1 |
| 2005 | 1 |
| 2006 | 3 |
| 2007 | 5 |
| 2008 | 1 |
| 2010 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 7
- Phase 2
- 5
- Phase 3
- 2
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 9 · Other 5
Agennix (9) · National Cancer Institute (NCI) (2) · Barbara Ann Karmanos Cancer Institute (1) · William K. Oh (1) · Yale University (1)
Often tested with
Tested in the same studies.
Prednisone (2) · Bevacizumab (1) · Albumin-Bound Paclitaxel (1) · Paclitaxel (1) · Docetaxel (1) · Capecitabine (1)
Studies
Open first, then newest update. How each study uses satraplatin is read from its arms, and is right about nine times in ten.
Testing it · 14
- Satraplatin and Prednisone to Treat Prostate CancerCompletedPhase 2National Cancer Institute (NCI)NCT00634647Written as Satraplatin
- Satraplatin in Children and Young Adults With Refractory Solid Tumors Including Brain TumorsCompletedPhase 1National Cancer Institute (NCI)NCT01259479Written as Satraplatin
- Satraplatin and Bevacizumab in Treating Patients With Metastatic Prostate Cancer Previously Treated With DocetaxelCompletedNot applicableBarbara Ann Karmanos Cancer InstituteNCT00499694Written as satraplatin
- Utilizing A Genomic Sig for "BRCAness" to Eval the Efficacy of Satraplatin in Men With Met. Castration Resistant Prostate CaCompletedPhase 2William K. OhNCT01289067Written as Satraplatin
- Phase I Study of the Combination of Satraplatin and Abraxane in Advanced CancersCompletedPhase 1Yale UniversityNCT00473720Written as Satraplatin
- Expanded Access Study of Satraplatin Plus Prednisone in Patients With Hormone Refractory Prostate Cancer (HRPC)TerminatedPhase 3AgennixNCT00450970Written as Oral Satraplatin
- Satraplatin for Locally Advanced Non-Small Cell Lung Cancer With Simultaneous RadiotherapyTerminatedPhase 1/2AgennixNCT00093132Written as Satraplatin
- A Study Comparing Sequential Satraplatin & Erlotinib to Erlotinib in Unresectable Stage 3/4 Non-small-cell Lung Cancer (NSCLC)CompletedPhase 2AgennixNCT00370383Written as Satraplatin
- Satraplatin in Hormone Refractory Prostate Cancer Patients Previously Treated With One Cytotoxic Chemotherapy RegimenCompletedPhase 3AgennixNCT00069745Written as Satraplatin
- A Phase I Study of the Oral Platinum Agent Satraplatin in Combination With Weekly DocetaxelTerminatedPhase 1AgennixNCT00313456Written as Satraplatin
- Satraplatin for Patients With Metastatic Breast Cancer (MBC)CompletedPhase 2AgennixNCT00265655Written as Satraplatin
- Study of Satraplatin (JM-216) in Combination With DocetaxelTerminatedPhase 1AgennixNCT00125411Written as satraplatin and docetaxel
- Study of Satraplatin With Capecitabine to Treat Advanced Solid MalignanciesTerminatedPhase 1AgennixNCT00329329Written as satraplatin and capecitabine
- A Phase I Trial of Satraplatin Plus Radiation Therapy for Prostate Cancer Patients With Biochemical RecurrenceTerminatedPhase 1AgennixNCT00480623Written as Satraplatin plus radiation therapy
Codes
What other systems call satraplatin · ClinicalTrials.gg INT003729
- MeSH (NLM) C081294satraplatinConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 8D7B37T28GSATRAPLATINConfirmed FDA, NLM
- RxNorm 1733681One source FDA
- NCI Thesaurus C1493SatraplatinOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C081294 | satraplatin | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 8D7B37T28G | SATRAPLATIN | Confirmed FDA, NLM |
| RxNorm | 1733681 | — | One source FDA |
| NCI Thesaurus | C1493 | Satraplatin | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.